Bharatuar A, Kar M, Khatri S, Goswami V, Sarin R, Dawood S, Iyenger R, Ganvir M, Parikh Purvish M, Aggarwal S, Talwar Vineet
Department of Medical Oncology, Patel Hospital, Jallandhar, Punjab, India.
Department of Medical Oncology, Peerless Hospital, Kolkata, West Bengal, India.
South Asian J Cancer. 2018 Apr-Jun;7(2):91-95. doi: 10.4103/sajc.sajc_109_18.
Bone-modifying therapy is a primary research interest in breast cancer. Several features contribute to the importance of the bone environment in the management of breast cancer. Firstly, bone metastases represent the most common site of breast cancer metastases and secondly, the emergence of cancer treatment-induced bone loss (CTIBL) among breast cancer survivors and patients is of increasing concern. In the adjuvant setting, bisphosphonates can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. Expert oncologists discusses on the update on the approaches of Bone-modifying Agents and its treatment options. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.
骨修饰疗法是乳腺癌主要的研究热点。骨环境在乳腺癌治疗中具有重要意义，这有几个方面的原因。首先，骨转移是乳腺癌最常见的转移部位；其次，乳腺癌幸存者和患者中癌症治疗引起的骨质流失（CTIBL）问题日益受到关注。在辅助治疗中，双膦酸盐可用于预防和治疗绝经前和绝经后女性的肿瘤治疗引起的骨质流失，并且由于其对骨转换有有益作用，也已被评估用于预防骨转移的发生。肿瘤学专家讨论了骨修饰剂的治疗方法及其治疗选择的最新进展。该专家小组利用已发表文献的数据、实践经验以及一大批学术肿瘤学家的意见，达成了这些实用的共识性建议，以造福社区肿瘤学家。
